Trial Profile
A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN/RBV Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms STARTVerso-3
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 25 Jan 2019 Peurto Rico, Taiwan and Romania are the planned locations according to European Clinical Trials Database record.
- 19 May 2014 Status changed from active, no longer recruiting to completed; according to ClinicalTrials.gov record.
- 02 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov record.